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Introduction 
This year the OPCW, the implementing body for the Chemical 
Weapons Convention, celebrates the 20th anniversary of entry 
into forces. In 2014, this organization examined the impact of 
new technologies in the field of chemical and biological weap-
ons, in particular the “Convergence” of Chemistry and Biology. 
An OPCW report of the Scientific Advisory Group highlighted 
the importance of monitoring developments in science and tech-
nology: “New production processes, combined with develop-
ments in drug discovery and delivery, could be exploited in the 
development of new toxic chemicals that could be used as weap-
ons.”1 Indeed, since 2008, Synthetic Biology is monitored also 
by other international organizations, such as the Nonproliferation 
Export Control Regimes Australia Group.2,3
Until now, the interest in Synthetic Biology research as a pro-
liferation risk,4,5,6 was essentially based on the possibility to cre-
ate from scratch lethal viruses; indeed, whole bacterial genomes 
can be now synthesized in laboratories and assembled in yeast 
cells and non-essential genes can be reshuffled and/or eliminated 
from the genome. A synthetic yeast genome itself is under con-
struction,7,8,9,10 (this field of Synthetic Biology is characterized 
by a bottom-up approach, Fig.1A). This achievement is consid-
ered a “Convergence” of Chemistry towards Biology because it 
is possible to construct a biological molecule, a genome, start-
ing with chemicals in laboratory.11 The second type of Synthetic 
Biology approach (top-down), has not been considered a threat 
because it is widely used to create new metabolic pathways in 
bacteria or yeasts, to produce new compounds such as biofuels, 
biologically active molecules (often of pharmaceutical value) 
and chemicals.12,13 Along this way, the synthesis and the inser-
tion of functional biological components into natural genomes 
is achieved creating metabolic pathways, often combining genes 
from different organisms. Unfortunately, recently, even this top-
down approach raised concerns for the possibility to produce tox-
ic chemicals from microorganisms.14 This type of experiments 
represents the “Convergence” of Biology towards Chemistry, 
because chemicals are produced by biological means.15,16 Yeasts 
are considered excellent cell factories for industrial applications, 
with the possibility to create engineered cells for efficient pro-
duction of a desired compound (metabolic engineering). In par-
ticular, the yeast Saccharomyces cerevisiae plays an essential 
role in this field,17 in addition to that of food industry (production 
of bread, beer, wine and chocolate). With yeasts, it is possible to 
produce pure amount of chemicals of high quality at low costs 
and with a standardised process and continuous production all 
over the year, independent from seasonal harvest.18 Of great in-
terest for the pharmaceutical industry, the biological synthesis 
could expand the chemical diversity of natural products and their 
structural complexity;19,20 indeed, model organisms are suitable 
for advancing new approaches to drug discovery. The most suc-
cessful production in yeast is the synthesis of the antimalarial 
artemisin precursor,21,22 Fig.1B, but S. cerevisiae has been used as 
a biomanufacturing platform for a large number of molecules.23,24 
In addition to biofuels (bioethanol and farnesene),25 high value 
metabolites were produced in yeast:26 penicillin,27 vindoline,28 
noscapine,29 anthranilates,30 raspberry ketone,31 resveratrol,32,24 
vanillin,33 rose oil and perfumes.34
Illicit Chemicals from Yeast Cells
For the first time, in 2015, illicit molecules (brain acting mole-
cules) were produced applying Synthetic Biology top-down ap-
proach to yeast cells. Concerns were raised when the  production 
of codeine and  morphine was achieved in S. cerevisiae:35,36 dif-
ferent groups successfully inserted genes from bacteria, opium 
poppy and sugar beet into yeast, reconstructing the pathway for 
morphine or codeine production.37,38,39 The entire biosynthetic 
pathway of thebaine (precursor of morphine) and hydrocodone 
has been achieved by inserting genes from plants, bacteria and 
mammals.40 The expression of the entire opiate pathway in a sin-
gle yeast cell has now become a reality but could be subject to 
misuse because anyone with access to morphine-producing yeast 
strains, and with basic fermentation skills, could easily produce 
morphine in large quantity, starting from glucose.41 Opioids are 
of great pharmaceutical value because are the primary analge-
sic alkaloids used for pain relief; the chemical synthesis of these 
molecules is not commercially competitive, when compared with 
the extraction from the Papaver somniferum plant; so, with Syn-
thetic Biology tools, it soon will be possible to produce cheaper, 
less addictive, safer and more effective analgesics. Another type 
of brain active molecules, which are used to inhibit inflammation 
and pain, are the cannabinoids, extracted from Cannabis sativa.42 
Cannabinoids act on human endocannabinoid system, which is 
involved in a wide array of bodily processes, including appetite, 
memory, pain and mood. Cannabis sativa plant makes over 100 
different types of cannabinoids, but the most important are tet-
rahydrocannabinol (THC), which is responsible of psychoactive 
effects, and cannabidiol (CBD), which has solely therapeutic ef-
fects. These molecules bind to different human cannabinoid re-
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Figure 1. Yeast in synthetic biology. a: Bottom-up approach. Yeast cells were used to assembly the first synthetic bacterial genome. 
The de novo synthesis of the Mycoplasma mycoides genome utilized synthetic DNA oligonucleotides assembled first in vitro and then in 
Saccharomyces cerevisiae. The whole construct was transplanted to Mycoplasma capricolum, yielding a viable organism. b: Top-down 
approach. Yeast as a cell factory for chemical production in biotechnology. 
ceptors: THC binds to the cannabinoid CB1 receptor in the brain 
triggering psychotropic and psychedelic effects, while the can-
nabidiol binding to the CB2 receptor has an anti-inflammatory 
effect. The obstacle to the wide use of cannabinoids in medicine 
is that the extraction of cannabidiol contains a small percentage 
of THC. The pharmaceutical industry is seeking a synthetic form 
of cannabis that inhibits inflammation and pain, but without the 
psychedelic or psychotropic effect. The advantage of using yeast 
to produce cannabinoids is that strains can be engineered to pro-
duce only solely therapeutic cannabinoids, like CBD, and not 
those that are psychedelic or psychotropic, like THC. In other 
words, yeast could be used to make pure products used for nutra-
ceutical or pharmaceutical purposes: until now, using yeast cells, 
Germany’s Technical University of Dortmund, achieved the pro-
duction of Δ9-tetrahydrocannabinol and cannabidiol; Canada’s 
Hyasynth Bio produced cannabigerol; England’s Anandia Lab-
oratories make cannabinoids and US BioTork LLC, cannabidiol.
Conclusions on Dual-Use Implication
The pharmaceutical interest on opioids and cannabinoids will 
result in a further future development of metabolic engineering 
pathways to improve the yields and produce other molecules 
acting in the brain. These discoveries could lead to the massive 
production of illicit drugsin fermenters, with cheap row materi-
als and in an easy way, in any place in the world. Unfortunately, 
yeast cells, thanks to the harmless nature of this organism, can be 
easily transported without biosafety restrictions.43 In the future, 
the bottom-up will meet the top-down technology and it will be 
possible to introduce into yeast synthetic genome the biological 
modules containing the entire biosynthetic opiates or cannabi-
noids pathways and select yeast cells overproducing morphine 
or cannabidiol. For the above reason, this type of experimenta-
tion should rise attention of the scientific community on the so 
called dual-use technology,44 being this the first case of produc-
tion of controlled narcotics by synthetic biology. In the light of 
the fast development of biotechnology, the outreach to academia 
should be as broad as possible, to capture the attention also of re-
searchers involved in basic science. In the short to medium term, 
Synthetic Biology is unlikely to pose new risks or threats, but 
the long-term possibility to insert foreign synthetic genes into 
a natural organism, with the aim of producing biological weap-
ons or drugs could turn even a harmless organism, such as the 
Saccharomyces cerevisiae into a dangerous threat. Toxins have 
already been expressed in microorganisms: bacterial toxins from 
Escherichia coli, Vibrio cholerae, Bacillus thuringiensis, Clos-
tridium botulinum and Clostridium tetani were successfully ex-
pressed in the yeast Pichia pastoris.45 The non-enzymatic heavy 
chain of the botulinum toxin B was expressed in yeast with the 
aim of expressing a secretory toxin antigen, and the subunit A 
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cerevisiae, to study how ricin kills the cells for the development 
of a protective ricin antidote.46,47 Finally, engineered anthrax tox-
in in bacteria was successfully used to selectively deliver toxic 
molecules in cancer cells, resulting in successful tumor therapy 
in animal models.48,49,50,51 The examples reported indicate that we 
are facing a real genomic and biotechnological revolution in life 
sciences and that researchers who manipulates GRAS organisms 
should also be aware of bio-threats in the future. Simple actions 
would be sufficient to prevent the unconscious spread of intan-
gible technologies or strains and plasmids among potential bio-
terrorists.43
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